

20427 U.S. PTO
031704

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

17497 U.S. PTO
10/802583
031704

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 17, 2004

Date of Deposit

Signature *Gene McInnis*

EL 964822675 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: **DEAV2003/0022 US NP**
INVENTORS: **HACHTEL, et al.**
TITLE: **PROCESS FOR PREPARING 2-CYANO-3-HYDROXY-N-(PHENYL)BUT-2-ENAMIDES**

APPLICATION ELEMENTS

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification Total Pages
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) Total Sheets
4. Oath or Declaration Total Pages
 - a. ☒ Newly unexecuted (original or copy)
 - b. ☐ Copy from a prior application (37 CFR § 1.63(d))
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. Power of Attorney Total Pages
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR § 1.63(d))
6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer Readable Copy
b. ☐ Paper Copy (identical to computer copy)
c. ☐ Statement verifying identity of above copies

☐ If a CONTINUING Application, check appropriate box, and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part

of prior application no: _____, filed _____,

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

- ☒ This application claims the benefit of U.S. Provisional Application No. 60/490,329, filed July 25, 2003 and claims priority to German Application No. DE10311763.6, filed March 18, 2003. (The cross reference has been/will be inserted on page one of the specification).

☐ **Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 CFR §3.73(b) Statement
(when there is an assignee)
9. ☐ Verified English Translation Document (if applicable)
10. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ 1 Copies of IDS Citations
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
14. ☒ Certified Copy of Priority Document(s) – DE10311763.6 of March 18, 2003
(if foreign priority is claimed)
15. ☒ Other: EPAVE – Application Data Sheet

CORRESPONDENCE ADDRESS

- ☒ Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


Ronald G. Ort, Reg. No. 26,969
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626
Aventis Docket No. DEAV2003/0022 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2004

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$)**1060.00****Complete if Known**

| | |
|----------------------|---------------------|
| Application Number | Not Yet Known |
| Filing Date | Herewith |
| First Named Inventor | HACHTEL |
| Examiner Name | |
| Group / Art Unit | |
| Attorney Docket No. | DEAV2003/0022 US NP |

METHOD OF PAYMENT (check all that apply)
☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None
☒ Deposit AccountDeposit
Account
Number
Deposit
Account
Name

18-1982

Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account
FEE CALCULATION**1. BASIC FILING FEE**

| Large Entity | Small Entity | Fee Description | Fee Paid |
|---------------|---------------|------------------------|----------|
| Fee Code (\$) | Fee Code (\$) | | |
| 1001 770 | 2001 375 | Utility filing fee | 770 |
| 1002 340 | 2002 165 | Design filing fee | |
| 1003 530 | 2003 260 | Plant filing fee | |
| 1004 770 | 2004 375 | Reissue filing fee | |
| 1005 160 | 2005 80 | Provisional filing fee | |

SUBTOTAL (1) (\$)**770.00****2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

| Total Claims | Extra Claims | Fee from below | Fee Paid |
|--------------------|--------------|----------------|----------|
| 16 | -20**= | | |
| Independent 1 | -3**= | | |
| Multiple Dependent | | 290 | 290 |

| Large Entity | Small Entity | Fee Description |
|---------------|---------------|---|
| Fee Code (\$) | Fee Code (\$) | |
| 1202 18 | 2202 9 | Claims in excess of 20 |
| 1201 86 | 2201 42 | Independent claims in excess of 3 |
| 1203 290 | 2203 140 | Multiple dependent claim, if not paid |
| 1204 86 | 2204 42 | **Reissue independent claims over original patent |
| 1205 18 | 2205 9 | **Reissue claims in excess of 20 and over original patent |

SUBTOTAL (2) (\$)**290.00**

**or number previously paid, if greater; For Reissues, see above


FEE CALCULATION (continued)**3. ADDITIONAL FEES**

| Large Entity | Small Entity | Fee Description | Fee Paid |
|---------------|---------------|--|----------|
| Fee Code (\$) | Fee Code (\$) | | |
| 1051 130 | 2051 65 | Surcharge - late filing fee or oath | |
| 1052 50 | 2052 25 | Surcharge - late provisional filing fee or cover sheet | |
| 1053 130 | 1053 130 | Non-English Specification | |
| 1812 2,520 | 1812 2,520 | For filing a request for reexamination | |
| 1804 920* | 1804 920* | Requesting publication of SIR prior to Examiner action | |
| 1805 1,840* | 1805 1,840* | Requesting publication of SIR after Examiner action | |
| 1251 110 | 2251 55 | Extension for reply within first month | |
| 1252 420 | 2252 205 | Extension for reply within second month | |
| 1253 950 | 2253 465 | Extension for reply within third month | |
| 1254 1,480 | 2254 725 | Extension for reply within fourth month | |
| 1255 2,010 | 2255 985 | Extension for reply within fifth month | |
| 1401 330 | 2401 160 | Notice of Appeal | |
| 1402 330 | 2402 160 | Filing a brief in support of an appeal | |
| 1403 290 | 2403 140 | Request for oral hearing | |
| 1451 1,510 | 1451 1,510 | Petition to institute a public use proceeding | |
| 1452 110 | 2452 55 | Petition to revive - unavoidable | |
| 1453 1,330 | 2453 650 | Petition to revive - unintentional | |
| 1501 1,330 | 2501 650 | Utility issue fee (or reissue) | |
| 1502 480 | 2502 235 | Design issue fee | |
| 1503 640 | 2503 315 | Plant issue fee | |
| 1460 130 | 1460 130 | Petitions to the Commissioner | |
| 1807 50 | 1807 50 | Petitions related to provisional applications | |
| 1806 180 | 1806 180 | Submission of Information Disclosure Stmt | |
| 8021 40 | 8021 40 | Recording each patent assignment per property (times number of properties) | |
| 1809 770 | 2809 375 | Filing a submission after final rejection (37 CFR § 1.129(a)) | |
| 1810 770 | 2810 375 | For each additional invention to be examined (37 CFR § 1.129(b)) | |
| 1801 770 | 2801 375 | Request for Continued Examination (RCE) | |
| 1802 900 | 1802 900 | Request for expedited examination of a design application | |

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**SUBMITTED BY****Complete (If applicable)**

| | | | | | |
|-------------------|---|-----------------------------------|--------|-----------|----------------|
| Name (Print/Type) | Ronald G. Ort, Reg. No. 26,969 | Registration No. (Attorney/Agent) | 26,969 | Telephone | (908) 231-4656 |
| Signature |  | | | Date | March 17, 2004 |

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template